BioMimetic Therapeutics Company Profile (NASDAQ:BMTI)

About BioMimetic Therapeutics (NASDAQ:BMTI)

BioMimetic Therapeutics logoBioMimetic Therapeutics, Inc. is a biotechnology company engaged in developing and commercializing products to the healing of musculoskeletal injuries and diseases, including therapies for orthopedic, sports medicine and spine applications. The Company's Augment platform of product and product candidates include an engineered version of recombinant human platelet-derived growth factor BB (rhPDGF-BB), one of the wound healing and tissue repair stimulators in the body. Its platform regenerative technology for promoting tissue healing and regeneration combines rhPDGF-BB with tissue specific matrices, when appropriate. The matrices are engineered or natural scaffold materials, such as Beta Tri-Calcium Phosphate. The Company's product candidates include Augment Bone Graft (Augment), Augmen Injectable Bone Graft (Augment Injectable) and Augment Rotator Cuff Graft (Augment Rotator Cuff Graft). In March 2013, Wright Medical Group Inc completed acquisition of BioMimetic Therapeutics, Inc.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BMTI
  • CUSIP: N/A
  • Web: N/A
P/E:
  • Trailing P/E Ratio:
  • P/E Growth:
Dividend:
  • Dividend Yield: 1.0%
 
Frequently Asked Questions for BioMimetic Therapeutics (NASDAQ:BMTI)

What is BioMimetic Therapeutics' stock symbol?

BioMimetic Therapeutics trades on the NASDAQ under the ticker symbol "BMTI."

Who are some of BioMimetic Therapeutics' key competitors?

How do I buy BioMimetic Therapeutics stock?

Shares of BioMimetic Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioMimetic Therapeutics' stock price today?

One share of BioMimetic Therapeutics stock can currently be purchased for approximately $9.49.


MarketBeat Community Rating for BioMimetic Therapeutics (NASDAQ BMTI)
Community Ranking:  1.5 out of 5 ( )
Outperform Votes:  11 (Vote Outperform)
Underperform Votes:  25 (Vote Underperform)
Total Votes:  36
MarketBeat's community ratings are surveys of what our community members think about BioMimetic Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for BioMimetic Therapeutics (NASDAQ:BMTI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for BioMimetic Therapeutics (NASDAQ:BMTI)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for BioMimetic Therapeutics (NASDAQ:BMTI)
Earnings by Quarter for BioMimetic Therapeutics (NASDAQ:BMTI)
Earnings History by Quarter for BioMimetic Therapeutics (NASDAQ BMTI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/5/2012Q312($0.23)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for BioMimetic Therapeutics (NASDAQ:BMTI)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for BioMimetic Therapeutics (NASDAQ:BMTI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for BioMimetic Therapeutics (NASDAQ:BMTI)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for BioMimetic Therapeutics (NASDAQ:BMTI)
Latest Headlines for BioMimetic Therapeutics (NASDAQ:BMTI)
Source:
No headlines for this company have been tracked by MarketBeat.com

Social

Chart

BioMimetic Therapeutics (BMTI) Chart for Tuesday, July, 25, 2017

This page was last updated on 7/25/2017 by MarketBeat.com Staff